OrbiMed sees ample opportunity to deploy $4.3B in new capital

With $4.3 billion in new capital across three private funds, OrbiMed believes the biotech bear market still presents plenty of investment opportunities across late-stage private and small-cap public companies, in particular for its royalty and credit fund.

On Tuesday, OrbiMed raised nearly $1.9 billion for its U.S. and European-focused VC flagship VC fund OrbiMed Private Investments IX; about $1.7 billion for OrbiMed Royalty & Credit Opportunities IV; and about $750 million for OrbiMed Asia Partners V. In March 2021, OrbiMed raised $3.5 billion across three private funds, including $1.5 billion for its eighth flagship VC fund...